open access
Vol 30, No 1 (2023)
Research Letter
Submitted: 2022-07-04
Accepted: 2022-11-18
Published online: 2023-01-30
Get Citation
Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
Shingo Kato12, Nobuyuki Horita3, Daisuke Utsunomiya2
Affiliations- Department of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
- Department of Diagnostic Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
- Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan
open access
Vol 30, No 1 (2023)
Research letters — Clinical cardiology
Submitted: 2022-07-04
Accepted: 2022-11-18
Published online: 2023-01-30
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
Journal
Issue
Article type
Research Letter
Pages
153-154
Published online
2023-01-30
Page views
462
Article views/downloads
134
DOI
10.5603/CJ.a2023.0004
Pubmed
Bibliographic record
Cardiol J 2023;30(1):153-154.
Authors
Shingo Kato
Nobuyuki Horita
Daisuke Utsunomiya
References (5)- Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013; 1(2): 93–102.
- Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–1461.
- McMurray JJV, Salomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
- Packer M, Anker S, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413–1424.
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with preserved ejection fraction. N Engl J Med. 2023; 388(3): 286–288.
